It is possible entyvio/vedolizumab has actually induced or exacerbated the issue.
https://ard.bmj.com/content/76/5/878.short"This is the first report on new onset or exacerbation of arthritis/sacroiliitis in vedolizumab treated patients. Despite the proven efficacy in IBD, both in anti-TNF-naive and in anti-TNF exposed patients, α4β7 blockade seems to facilitate synovitis with similar distribution to SpA in some patients, irrespective of the response to treatment at the level of the gut"